Compare, Analyse Aurobindo Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs MYLAN (US) - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   MYLAN
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
MYLAN
Dec-18
AUROBINDO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs8093,390-   
Low Rs5041,866-   
Sales per share (Unadj.) Rs281.11,559.9-  
Earnings per share (Unadj.) Rs41.442.4-  
Cash flow per share (Unadj.) Rs50.9334.4-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.41,687.5-  
Shares outstanding (eoy) m585.88514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.31.7 138.6%   
Avg P/E ratio x15.962.0 25.6%  
P/CF ratio (eoy) x12.97.9 164.2%  
Price / Book Value ratio x3.31.6 211.5%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,6301,352,115 28.4%   
No. of employees `00017.335.0 49.5%   
Total wages/salary Rs m21,3080-   
Avg. sales/employee Rs Th9,500.722,930.8 41.4%   
Avg. wages/employee Rs Th1,229.40-   
Avg. net profit/employee Rs Th1,397.9622.7 224.5%   
INCOME DATA
Net Sales Rs m164,666802,578 20.5%  
Other income Rs m1,0200-   
Total revenues Rs m165,686802,578 20.6%   
Gross profit Rs m37,718207,678 18.2%  
Depreciation Rs m5,580150,274 3.7%   
Interest Rs m77738,601 2.0%   
Profit before tax Rs m32,38018,802 172.2%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183-2,991 -273.6%   
Profit after tax Rs m24,22921,793 111.2%  
Gross profit margin %22.925.9 88.5%  
Effective tax rate %25.3-15.9 -158.8%   
Net profit margin %14.72.7 541.9%  
BALANCE SHEET DATA
Current assets Rs m121,878448,159 27.2%   
Current liabilities Rs m86,806326,757 26.6%   
Net working cap to sales %21.315.1 140.8%  
Current ratio x1.41.4 102.4%  
Inventory Days Days13084 155.4%  
Debtors Days Days6893 73.3%  
Net fixed assets Rs m81,037155,687 52.1%   
Share capital Rs m586427 137.1%   
"Free" reserves Rs m116,2180-   
Net worth Rs m116,804868,243 13.5%   
Long term debt Rs m4,512937,113 0.5%   
Total assets Rs m211,0522,328,965 9.1%  
Interest coverage x42.71.5 2,868.9%   
Debt to equity ratio x01.1 3.6%  
Sales to assets ratio x0.80.3 226.4%   
Return on assets %11.82.6 456.9%  
Return on equity %20.72.5 826.4%  
Return on capital %27.43.2 860.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m46,0270-   
CASH FLOW
From Operations Rs m19,548166,776 11.7%  
From Investments Rs m-19,570-86,205 22.7%  
From Financial Activity Rs m8,642-77,694 -11.1%  
Net Cashflow Rs m8,9221,382 645.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.22 Rs / USD

Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: SHASUN PHARMA  NATCO PHARMA  GSK PHARMA  PFIZER  TTK HEALTHCARE  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views On News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS